Bright Minds Biosciences announces participation in the upcoming scientific conferences and partnering events

DRUG 10.03.2024

SERA-AI Powered Highlights
Full Press ReleaseSEC FilingsOur DRUG Tweets

About Gravity Analytica

Recent News

  • 01.07.2025 - Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
  • 11.21.2024 - Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
  • 11.05.2024 - BRIGHT MINDS BIOSCIENCES CLOSES US$35 MILLION NON-BROKERED PRIVATE PLACEMENT

Recent Filings

  • 01.08.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
  • 01.08.2025 - EX-99.1 EX-99.1
  • 12.31.2024 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
Failed
Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com